How Eucalyptus ‘circumnavigated’ Australian medical marketing rules to a $1.6b sale

When health start-up Eucalyptus launched in 2019, its four founders could hardly have predicted that a little-known diabetes drug, GLP-1 would take them to a $1.6 billion sale in just seven years.

Fast-forward to today, and ads for the start-up’s telehealth service Juniper are unavoidable, with everything from celebrity TV spots to Black Friday deals introducing Australians to fast-track weight-loss GLP-1 drugs Wegovy and Mounjaro.

How Eucalyptus achieved this in Australia — one of the world’s strictest regulatory markets for pharmaceutical marketing — is, in the words of a former medical marketer, “arguably one of the best examples of circumnavigating the rules ever seen.”

Be a member to keep reading

Join Mumbrella Pro to access the Mumbrella archive and read our premium analysis of everything under the media and marketing umbrella.

Become a member

Get the latest media and marketing industry news (and views) direct to your inbox.

Sign up to the free Mumbrella newsletter now.

"*" indicates required fields

 

SUBSCRIBE

Sign up to our free daily update to get the latest in media and marketing.